These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15886796)
1. Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. Lewis DA; Bovenschen N; Mertens K; Voorberg J; Ortel TL Thromb Haemost; 2005 May; 93(5):833-41. PubMed ID: 15886796 [TBL] [Abstract][Full Text] [Related]
2. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. Lewis DA; Moore KD; Ortel TL Blood Coagul Fibrinolysis; 2003 Jun; 14(4):361-8. PubMed ID: 12945878 [TBL] [Abstract][Full Text] [Related]
3. Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Lewis DA; Pound ML; Ortel TL Thromb Haemost; 2003 May; 89(5):795-802. PubMed ID: 12719775 [TBL] [Abstract][Full Text] [Related]
4. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. van den Brink EN; Turenhout EA; Bovenschen N; Heijnen BG; Mertens K; Peters M; Voorberg J Blood; 2001 Feb; 97(4):966-72. PubMed ID: 11159524 [TBL] [Abstract][Full Text] [Related]
5. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P Blood; 2001 Jan; 97(1):169-74. PubMed ID: 11133757 [TBL] [Abstract][Full Text] [Related]
6. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Takeshima K; Smith C; Tait J; Fujikawa K Thromb Haemost; 2003 May; 89(5):788-94. PubMed ID: 12719774 [TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. van den Brink EN; Turenhout EA; Bank CM; Fijnvandraat K; Peters M; Voorberg J Blood; 2000 Jul; 96(2):540-5. PubMed ID: 10887116 [TBL] [Abstract][Full Text] [Related]
8. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Saleh M; Peng W; Quinn-Allen MA; Macedo-Ribeiro S; Fuentes-Prior P; Bode W; Kane WH Thromb Haemost; 2004 Jan; 91(1):16-27. PubMed ID: 14691564 [TBL] [Abstract][Full Text] [Related]
9. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism. Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079 [TBL] [Abstract][Full Text] [Related]
10. Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity. Meems H; Meijer AB; Cullinan DB; Mertens K; Gilbert GE Blood; 2009 Oct; 114(18):3938-46. PubMed ID: 19687511 [TBL] [Abstract][Full Text] [Related]
11. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848 [TBL] [Abstract][Full Text] [Related]
13. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643 [TBL] [Abstract][Full Text] [Related]
14. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII. Voorberg J; van den Brink EN Semin Thromb Hemost; 2000; 26(2):143-50. PubMed ID: 10919406 [TBL] [Abstract][Full Text] [Related]
15. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody. Lin JC; Ettinger RA; Schuman JT; Zhang AH; Wamiq-Adhami M; Nguyen PC; Nakaya-Fletcher SM; Puranik K; Thompson AR; Pratt KP PLoS One; 2015; 10(1):e0116577. PubMed ID: 25615825 [TBL] [Abstract][Full Text] [Related]
16. Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. Spaargaren J; Giesen PL; Janssen MP; Voorberg J; Willems GM; van Mourik JA Biochem J; 1995 Sep; 310 ( Pt 2)(Pt 2):539-45. PubMed ID: 7654192 [TBL] [Abstract][Full Text] [Related]
17. Role of factor VIII C2 domain in factor VIII binding to factor Xa. Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497 [TBL] [Abstract][Full Text] [Related]
18. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. Nogami K; Shima M; Hosokawa K; Nagata M; Koide T; Saenko EL; Tanaka I; Shibata M; Yoshioka A J Biol Chem; 2000 Aug; 275(33):25774-80. PubMed ID: 10831589 [TBL] [Abstract][Full Text] [Related]
19. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. Wakabayashi H; Freas J; Zhou Q; Fay PJ J Biol Chem; 2004 Mar; 279(13):12677-84. PubMed ID: 14722121 [TBL] [Abstract][Full Text] [Related]
20. Unsaturated phospholipid acyl chains are required to constitute membrane binding sites for factor VIII. Gilbert GE; Arena AA Biochemistry; 1998 Sep; 37(39):13526-35. PubMed ID: 9753438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]